Clinical trial

Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)

NCT05613842

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-08-09

PhasePHASE2

Study timeline

Study start (actual)2022-08-09Date precision: day

Registry last updated2023-09-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Copper-64 labelled SAR-BombesinDRUG

Sponsors & collaborators

St Vincent's Hospital, Sydneylead sponsor

Clarity Pharmaceuticals Ltdcollaborator

Mapped research locations

SydneyNew South Wales, Australia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05613842 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.